#orexo announce progress in the collab. with Abera Bioscience with the ambition to develop vaccines of the future. In-vivo study data shows the influenza vaccine is effective both as liquid & when formulated as a powder using the AmorphOX technology. orexo.com/media/detail?s…

We are approaching announcement for the Q1 Interim Report. On May 6 at 8 am CEST we will share the latest operational & financial developments. Later that day investors, analysts & media are invited to join our quarterly call. #orexo For details ▶️: orexo.com/media/detail?s…

Nyligen meddelade vi framsteg i samarbetet med Aberas där vi siktar på att utvecka nya vacciner. Nyfiken på att veta mer? Kom och lyssna när #Orexo s forskningschef Robert Rönn, tillsammans med Aberas VD Maria Alriksson håller en presentation. Anmälan: uppsala-business-park.confetti.events/life-after-work

Yesterday, Orexo announced its Q1 interim report – 'Stable commercial business in a volatile market.' The video below summarizes our financial and operational developments, as well as how we are mitigating external uncertainties. The full report ▶️ orexo.com.

Q1 2025 Interview with Orexo CEO Nikolaj Sørensen | Insights & Triggers youtu.be/DsVNMN8XMyU?si… via YouTube

Orexo is delighted to welcome Friedrich von Bohlen as chairman of our board following his appointment at the AGM on 8 May. We’ll be publishing an interview with Friedrich on our website soon, but in the meantime, read more in our PR: orexo.com/media/detail?s…

IR-presentation. Vi ser fram emot att delta på ABG Sundal Collier investerardagar 13-14 maj. Imorgon kl 8.45 ger VD Nikolaj Sørensen en bolagspresentation. För dem som ej delar på plats kommer en PDF läggas upp på webben. En inspelad version blir tillgänglig inom kort. STAY TUNED. #orexo

🎙️ Lyssna på VD Nikolaj Sørensen från ABGSC investerardagar. Fokus: ▶️ USA-närvaro & opioidkrisen ▶️ AmorphOX – skalbar pulverteknologi ▶️ Pipeline-projekt ▶️ Finansiell utveckling ▶️ Strategiska prioriteringar #orexo youtu.be/R5znYe6xN4s?si… via YouTube

Throwback to last week´s presentations ▶️ 1️⃣CEO Nikolaj Sorensen at ABGSC, talking about Q1 developments & priorities to drive growth 2️⃣SVP & Head of R&D Robert Rönn & Maria Alriksson CEO @Abera presented the collab developing nasal powder-based vaccines using AmorphOX. #orexo

På tisdag - 10 juni - kan du lyssna på när VD Nikolaj Sørensen presenterar #Orexo Aktiespararna #Aktiedagen. Fokus kommer ligga på den senaste utvecklingen inom US Commercial samt Product Development #amorphOX och strategin framåt för att driva tillväxt ▶️aktiespararna.se/aktiviteter/ak…

Orexo - Aktiedagarna Aktiespararna 10/6: ▶️Lång erfarenhet av produktutveckling för globala marknader ▶️Kassagenerator i USA #opioidkrisen ▶️Ledande pulverteknologi #amorphOX #pipeline ▶️Tydlig tillväxtstrategi youtu.be/z8H3H_mfl1Y?si… via YouTube

A key part of Orexo’s growth strategy is to capitalize on our next-generation drug delivery technology — AmorphOX. This scalable platform offers multiple opportunities, and partnerships can generate substantial value for all companies involved.

This wknd 1(2): We were delighted to have Dr. Anne Ellis, Prof. & Chair of the Division of Allergy & Immunology Queen’s University, CA, presenting positive data from the 2nd OX640 clinical study — e.g. highlighting its efficacy also in patients with allergic rhinitis #EAACI2025

This wknd 2(2): #Orexo SVP & Head of RnD & our Scientific Dir. also attended #EAACI2025. Both presented a research poster ‘Epinephrine Nasal Powder – a sustainable and reliable alternative for the treatment of #anaphylaxis’, which highlighted OX640´s superior stability profile.

Join us on July 16 at 2 pm CEST for a live presentation of Orexo’s Q2 Report. Get the latest updates & insights, followed by a Q&A. 👉 Report published at 8 am CEST the same day. #opioidcrisis #drugdevelopment #AmorphOX + info shorturl.at/CHauI

❤️🤍💙As we celebrate the #independenceday2025 let's take a moment to reflect on the ongoing opioid epidemic. At Orexo we are committed making a difference for those affected through innovative treatments. Together we can overcome the challenges & build a brighter future for all

Powder-based #drugdelivery is transforming medicine. With AmorphOX®, Orexo leads the way in nasal delivery of stable, fast-acting therapeutics — no cold chain needed to maintain efficacy. Learn how we're shaping the future: 👉lnkd.in/dcnfmjFB #Pharma #Innovation #Biotech

#Orexo Q2 Net Sales down mainly due to FX & one-time rebate. EBITDA negative but would’ve been positive excl. rebate. Cash position slightly up. Outlook reaffirmed Pipeline • OX124 ready for commercial mfg • Strong partner interest in OX640 • AmorphOX can stabilizes vaccines

Latest update 📽️. View video where Orexo’s CEO summerizes highlights & challenges in Q2 & where the focus lays ahead. #outlookreaffirmed youtu.be/7uXk15xTaXo

Orexo runs the🌍only commercial production line for dry powder epinephrine, using the only available nasal powder device. The facility has capacity to accelerate production of nasal rescue meds, powered by the AmorphOX technology. Below: subsite for OX640 commercial production.